#Switzerland #ADC Therapeutics #Lausanne #AACR 2025 #antibody-drug conjugates

ADC Therapeutics to Present at the AACR Annual Meeting 2025

In an exciting development for the cancer research community, ADC Therapeutics SA, a leader in the field of antibody-drug conjugates (ADCs), has announced that several research abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting scheduled for April 25-30, 2025, in Chicago, Illinois.

This prestigious meeting is set to showcase some of the most innovative and cutting-edge research in the oncology field, and ADC Therapeutics is at the forefront of this movement, particularly with its advancements in targeting various cancers through its proprietary ADC technologies.

Highlights of the Presentations

Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics, expressed enthusiasm regarding the presentations, stating, "We are excited to present preclinical data on our exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug conjugates. These ADCs hold promise for targeted cancer treatment in a broad range of cancer types, and we are pleased to have the opportunity to share our learnings across select solid tumors where there remains unmet need."

The company will feature an oral presentation detailing a groundbreaking preclinical investigation of ADCT-242, a novel exatecan-based ADC that targets Claudin-6. This presentation will delve into its effectiveness as a single agent and in combination therapies in models of ovarian and non-small lung cancer. Here are the specifics of this engaging session:

• - Title: Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models
• - Abstract Number: 1163
• - Session Category: Experimental and Molecular Therapeutics
• - Session Title: Antibody-Based Cancer Therapeutic Agents
• - Date and Time: Sunday, April 27, 2025, from 3:00 PM to 5:00 PM CT
• - Presenter: Chris Pickford, Head of Clinical Research, ADC Therapeutics

In addition to the oral presentation, ADC Therapeutics will also have two poster presentations that showcase further preclinical development efforts. One of the posters will cover ADCT-241, another novel exatecan-based ADC specifically targeting PSMA, aimed at treating prostate cancer. The details are as follows:

• - Title: Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer
• - Abstract Number: 6736
• - Session Category: Experimental and Molecular Therapeutics
• - Session Title: Antibody-Based Cancer Therapeutics 4
• - Date and Time: Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT
• - Presenter: Ben Leatherdale, Senior Scientist, ADC Therapeutics

The second poster will present HuB14-VA-PL2202, an innovative ADC targeting ASCT2, noted for its overexpression in both solid and hematological cancers, with the following details:

• - Title: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers
• - Abstract Number: 1580
• - Session Category: Experimental and Molecular Therapeutics
• - Session Title: Antibody-Based Cancer Therapeutics 1
• - Date and Time: Monday, April 28, 2025, from 9:00 AM to 12:00 PM CT
• - Presenter: Danilo Cucchi, Senior Scientist, ADC Therapeutics

About ADC Therapeutics

ADC Therapeutics is based in Lausanne, Switzerland and operates globally, including locations in London and New Jersey. The company is especially known for its ADC technology, which aims to revolutionize the treatment of various malignancies. Notably, its CD19-directed ADC, ZYNLONTA (loncastuximab tesirine-lpyl), received accelerated approval from the FDA for treating certain lymphomas, showcasing the efficacy of such targeted therapies across different types of cancer.

With an ambitious research agenda and a commitment to enhancing cancer treatments, ADC Therapeutics is clearly poised for significant contributions to the oncology field in the months and years ahead. For further details on their ongoing projects, interactive conversations, and latest updates, visit their official website or follow their LinkedIn page.